Last kr1.94 DKK
Change Today 0.00 / 0.00%
Volume 733.1K
VELO On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
OTC US
As of 11:01 AM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

veloxis pharmaceuticals a/s (VELO) Snapshot

Open
kr1.95
Previous Close
kr1.94
Day High
kr1.97
Day Low
kr1.92
52 Week High
07/4/14 - kr2.30
52 Week Low
10/22/13 - kr0.59
Market Cap
3.2B
Average Volume 10 Days
1.5M
EPS TTM
kr-0.06
Shares Outstanding
1.7B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VELOXIS PHARMACEUTICALS A/S (VELO)

Related News

No related news articles were found.

veloxis pharmaceuticals a/s (VELO) Related Businessweek News

No Related Businessweek News Found

veloxis pharmaceuticals a/s (VELO) Details

Veloxis Pharmaceuticals A/S operates as a specialty pharmaceutical company. Its proprietary technology, MeltDose is used to enhance the absorption and bioavailability of compounds the creation of various marketed drugs. The company develops and commercializes Envarsus, a once-daily dosage tablet version of tacrolimus for the prevention of organ rejection in kidney transplant patients; and has completed Phase II clinical studies for patients who have undergone a liver transplant. Its products also comprises Fenoglide for the treatment of dyslipidemia in the United States market; and AtorFen, which has completed Phase II clinical studies for the treatment of dyslipidemia. The company was formerly known as LifeCycle Pharma A/S and changed its name to Veloxis Pharmaceuticals A/S in July 2011. Veloxis Pharmaceuticals A/S is based in Hørsholm, Denmark.

23 Employees
Last Reported Date: 08/20/14

veloxis pharmaceuticals a/s (VELO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

veloxis pharmaceuticals a/s (VELO) Key Developments

Veloxis Pharmaceuticals A/S Announces Amendment to Articles of Association

Veloxis Pharmaceuticals A/S announced that amendment to the Articles of Association associated with the issue of warrants has been registered with the Danish Business Authority.

Veloxis Pharmaceuticals A/S Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year 2014

Veloxis Pharmaceuticals A/S announced consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue was DKK 12,206,000 compared with DKK 6,868,000 a year ago. Operating loss was DKK 35,850,000 compared with DKK 42,738,000 a year ago. Loss before tax was DKK 34,622,000 compared with DKK 44,991,000 a year ago. Net loss for the period was DKK 33,127,000 compared with DKK 44,750,000 a year ago. Basic and diluted earnings per share were DKK 0.02 compared with DKK 0.03 a year ago. Cash flow used in operating activities was DKK 33,577,000 compared with DKK 51,165,000 a year ago. Purchase of property, plant and equipment was DKK 169,000. For the six months, the company reported revenue was DKK 24,412,000 compared with DKK 13,736,000 a year ago. Operating loss was DKK 58,017,000 compared with DKK 82,594,000 a year ago. Loss before tax was DKK 56,112,000 compared with DKK 80,940,000 a year ago. Net loss for the period was DKK 53,123,000 compared with DKK 80,455,000 a year ago. Basic and diluted earnings per share were DKK 0.03 compared with DKK 0.05 a year ago. Cash flow used in operating activities was DKK 67,126,000 compared with DKK 96,290,000 a year ago. Purchase of property, plant and equipment was DKK 177,000. The company expects operating loss of DKK 60 million to 90 million and a net loss of DKK 55 million to 85 million for the financial year 2014. As at 30 June 2014, the company's cash position equaled DKK 264.2 million, and as at 31 December 2014, the company's cash position is expected to be in the range of DKK 230 million to 270 million.

Veloxis Pharmaceuticals A/S, Q2 2014 Earnings Call, Aug 21, 2014

Veloxis Pharmaceuticals A/S, Q2 2014 Earnings Call, Aug 21, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VELO:DC kr1.94 DKK 0.00

VELO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €7.99 EUR +0.124
Flamel Technologies SA $13.00 USD +0.33
Onxeo €6.20 EUR +0.20
Oxford Biomedica PLC 4.00 GBp 0.00
Supernus Pharmaceuticals Inc $7.80 USD +0.01
View Industry Companies
 

Industry Analysis

VELO

Industry Average

Valuation VELO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 61.0x
Price/Book 12.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 55.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VELOXIS PHARMACEUTICALS A/S, please visit www.veloxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.